

# Irene Hallyburton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9519134/publications.pdf>

Version: 2024-02-01

31  
papers

1,905  
citations

394286

19  
h-index

414303

32  
g-index

35  
all docs

35  
docs citations

35  
times ranked

3051  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preparation, biological & cheminformatics-based assessment of N2,N4-diphenylpyrimidine-2,4-diamine as potential Kinase-targeted antimalarials. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 46, 116348.	1.4	5
2	Potent antiplasmodial alkaloids from the rhizobacterium <i>Pantoea agglomerans</i> as hemozoin modulators. <i>Bioorganic Chemistry</i> , 2021, 115, 105215.	2.0	3
3	An Open Drug Discovery Competition: Experimental Validation of Predictive Models in a Series of Novel Antimalarials. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 16450-16463.	2.9	8
4	Nonclassical Phenyl Bioisosteres as Effective Replacements in a Series of Novel Open-Source Antimalarials. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11585-11601.	2.9	60
5	Escaping from Flatland: Antimalarial Activity of sp <sup>3</sup> -Rich Bridged Pyrrolidine Derivatives. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2497-2503.	1.3	10
6	Substituted Aminoacetamides as Novel Leads for Malaria Treatment. <i>ChemMedChem</i> , 2019, 14, 1329-1335.	1.6	5
7	Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7015-7020.	3.3	94
8	Pharmacological Validation of <i>N</i> -Myristoyltransferase as a Drug Target in <i>Leishmania donovani</i> . <i>ACS Infectious Diseases</i> , 2019, 5, 111-122.	1.8	55
9	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant <i>N</i> -Myristoyltransferase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8374-8389.	2.9	41
10	Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the <i>Plasmodium falciparum</i> Drug Target, Prolyl-tRNA-synthetase. <i>ACS Infectious Diseases</i> , 2017, 3, 34-44.	1.8	45
11	Screening a protein kinase inhibitor library against <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2017, 16, 446.	0.8	12
12	Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9672-9685.	2.9	66
13	Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. <i>ACS Central Science</i> , 2016, 2, 687-701.	5.3	68
14	Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6101-6120.	2.9	13
15	Discovery of Inhibitors of <i>Trypanosoma brucei</i> by Phenotypic Screening of a Focused Protein Kinase Library. <i>ChemMedChem</i> , 2015, 10, 1809-1820.	1.6	15
16	Development of Small Molecule <i>Trypanosoma brucei</i> <i>N</i> -Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. <i>ChemMedChem</i> , 2015, 10, 1821-1836.	1.6	20
17	A novel multiple-stage antimalarial agent that inhibits protein synthesis. <i>Nature</i> , 2015, 522, 315-320.	13.7	353
18	Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of <i>Trypanosoma brucei</i> . <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7695-7706.	2.9	28

#	ARTICLE	IF	CITATIONS
19	Lead Optimization of a Pyrazole Sulfonamide Series of <i>N</i> -Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9855-9869.	2.9	57
20	Induction of diverse secondary metabolites in <i>Aspergillus fumigatus</i> by microbial co-culture. <i>RSC Advances</i> , 2013, 3, 14444.	1.7	104
21	Comparison of a High-Throughput High-Content Intracellular <i>Leishmania donovani</i> Assay with an Axenic Amastigote Assay. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2913-2922.	1.4	135
22	Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1762.	1.3	93
23	Discovery of a Novel Class of Orally Active Trypanocidal <i>N</i> -Myristoyltransferase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 140-152.	2.9	102
24	Quinol derivatives as potential trypanocidal agents. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 1607-1615.	1.4	17
25	Optimisation of the Anti- <i>Trypanosoma brucei</i> Activity of the Opioid Agonist U50488. <i>ChemMedChem</i> , 2011, 6, 1832-1840.	1.6	7
26	Identification of a $\mu$ -opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. <i>Biochemical Pharmacology</i> , 2010, 80, 1478-1486.	2.0	69
27	<i>N</i> -myristoyltransferase inhibitors as new leads to treat sleeping sickness. <i>Nature</i> , 2010, 464, 728-732.	13.7	272
28	The hepatic PP1 glycogen-targeting subunit interaction with phosphorylase $\alpha$ can be blocked by C-terminal tyrosine deletion or an indole drug. <i>FEBS Letters</i> , 2007, 581, 4749-4753.	1.3	26
29	Initiating a crystallographic analysis of recombinant (S)-2-hydroxypropylphosphonic acid epoxidase from <i>Streptomyces wedmorensis</i> . <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2005, 61, 534-536.	0.7	3
30	The Suppression of Galactose Metabolism in Procyclic Form <i>Trypanosoma brucei</i> Causes Cessation of Cell Growth and Alters Procyclin Glycoprotein Structure and Copy Number. <i>Journal of Biological Chemistry</i> , 2005, 280, 19728-19736.	1.6	70
31	Hexameric Assembly of the Bifunctional Methylerythritol 2,4-Cyclodiphosphate Synthase and Protein-Protein Associations in the Deoxy-xylulose-dependent Pathway of Isoprenoid Precursor Biosynthesis. <i>Journal of Biological Chemistry</i> , 2004, 279, 52753-52761.	1.6	43